Please login to the form below

Not currently logged in
Email:
Password:

Teva takes majority stake in Taiyo

Israel's Teva is to take 57 per cent share in Japanese generic medicines manufacturer Taiyo

Teva Pharmaceutical Industries has signed a definite agreement to acquire 57 per cent of the share held in privately-owned Taiyo Pharmaceutical Industry Company for $460m in cash.

Shlomo Yanai, Teva president and chief executive, said: "This acquisition will enable Teva to deliver on our strategic objective of becoming a leading player in the fast-growing Japanese generics market. In fact, we now expect to reach our 2015 target of $1bn sales in Japan ahead of schedule."

The deal is subject to the approval of Taiyo's shareholder meeting, but it is expected to be complete by the end of September.

Meanwhile Teva has won the largest share of a new drug delivery tender by Germany's largest healthcare fund Allgemeinen Orstskrankassen. It secured 152 two-year supply contracts, 27 per cent of the contracts in the tender. The contracts come into effect on June 1.

16th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics